 | | Vol. 14.20 – 2 June, 2022 |
| |
|
|
| Scientists compared the placental transcriptomes of Tibetans, sea level Hans, and Han immigrants. Among the three populations, placentas from ImHan showed a hyperactive gene expression pattern.
[Molecular Biology and Evolution] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers reported a novel mechanism whereby kinase mutants induced intracellular alkalization characteristic in oncogenesis.
[Leukemia] |
|
|
|
| Investigators found that human umbilical cord MSCs-exosomes could colonize injured pancreatic tissue, inhibit the apoptosis of acinar cells, and control the systemic inflammatory response to facilitate the repair of pancreatic tissue.
[Stem Cell Research & Therapy] |
|
|
|
| The authors generated long-term stromal cell-derived factor-1 secreting human amniotic MSCs via TALEN-mediated editing and investigated to determine whether gene-edited AMM/S are novel angio-vasculogenic cell population in experimental ischaemia.
[Journal of Cellular and Molecular Medicine] |
|
|
|
| Researchers suggested that the magnetic fields could potentially induce proliferation of MSCs.
[Scientific Reports] |
|
|
|
| CD34+ hematopoietic stem cells were isolated from human umbilical cord blood and differentiated toward erythrocyte lineage for 14 days in various concentrations of indoxyl sulfate (IS). The effects of IS on cell proliferation, differentiation, apoptosis, and senescence were determined.
[Experimental Biology and Medicine] |
|
|
|
| Scientists investigated the effects of chronic hypoxia and sex on protein expression of the Insulin-like growth factor (IGF-2) pathway in placentas selected from asymmetric-fetal growth restriction fetuses.
[Reproductive Sciences] |
|
|
|
|
| Despite notable recent clinical and commercial successes, cell-based therapies continue to face numerous challenges that limit their widespread translation and commercialization, including identification of the appropriate cell source, generation of a sufficiently viable, potent and safe product that meets patient- and disease-specific need.
[Nature Reviews Drug Discovery] |
|
|
|
|
| Altos Labsâ„¢ launched as a new biotechnology company dedicated to unraveling the deep biology of cellular rejuvenation programming with a mission to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life.
[Altos Labsâ„¢ (PR Newswire)] |
|
|
|
|
| September 19 – 20, 2022
Vejle, Denmark |
|
|
|
|
|
| | Luna Genetics, Inc. – Houston, Texas, United States |
|
|
|
| | New York University College of Dentistry – New York, New York, United States |
|
|
|
| | Albert Einstein College of Medicine – New York, New York, United States |
|
|
|
| | Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| | Van Andel Institute – Grand Rapids, Michigan, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
